Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A. Friedman Buys 4,000 Shares
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) CEO Paul A. Friedman acquired 4,000 shares of Madrigal Pharmaceuticals stock in a transaction dated Monday, November 19th. The shares were purchased at an average cost of $124.00 per share, with a total value of $496,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ MDGL opened at $120.50 on Tuesday. Madrigal Pharmaceuticals Inc has a 52 week low of $40.28 and a 52 week high of $325.98. The company has a market cap of $2.00 billion, a P/E ratio of -47.44 and a beta of 1.56.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03). Equities analysts predict that Madrigal Pharmaceuticals Inc will post -2.19 EPS for the current fiscal year.
Several research analysts have recently weighed in on the company. BidaskClub cut Madrigal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Raymond James cut Madrigal Pharmaceuticals from a “market perform” rating to an “underperform” rating in a research report on Monday. Oppenheimer reduced their price objective on Madrigal Pharmaceuticals from $300.00 to $200.00 and set an “outperform” rating for the company in a research report on Monday. Evercore ISI raised Madrigal Pharmaceuticals from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $222.00 to $250.00 in a research report on Friday. Finally, Citigroup assumed coverage on Madrigal Pharmaceuticals in a research report on Tuesday, September 4th. They set a “buy” rating and a $340.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. Madrigal Pharmaceuticals currently has an average rating of “Hold” and an average target price of $297.63.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
See Also: Rule of 72
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.